growth hormone deficiency
Endocrinology · 2016–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| somatropin Treatment of severe late onset growth hormone deficiency (GHD) in adults. | Sep 2023 | Recommended with restriction | none received |
| somapacitan Treatment of paediatric patients with growth hormone deficiency (GHD), including short stature associated with biochemical GHD and short stature slow growth. | Jul 2023 | Recommended with restriction | 4 individuals |
| somapacitan Treatment of adult growth hormone deficiency (AGHD) in patients aged 18 years and above, and those under 18 years of age with a mature skeleton. | Mar 2022 | Recommended with restriction | 10 individuals Australian Pituitary Foundation |
| somatrogon Treatment of growth hormone deficiency (GHD) in paediatric patients, including short stature associated with biochemical growth hormone deficiency (SSABGHD)… | Mar 2022 | Recommended with restriction | 12 individuals Australian Pituitary Foundation |
| somatropin Treatment of adults with severe growth hormone deficiency, specifically childhood-onset growth hormone deficiency due to congenital, genetic or structural… | Aug 2019 | Noted | no section in document |
| somatropin Treatment of adults with severe growth hormone deficiency. The submission concerns the requirement for prescribers to use the Quality of Life in Adult Growth… | Mar 2019 | Recommended with restriction | no section in document |
| somatropin Short stature and slow growth in children requiring growth hormone therapy. | Jul 2018 | Recommended with restriction | none received |
| somatropin Treatment of adults with severe growth hormone deficiency (GHD) with substantially impaired quality of life at baseline. | Jul 2017 | Recommended with restriction | none received |
| somatropin Growth hormone deficiency in children and adults, including short stature due to decreased or failed secretion of pituitary growth hormone, severe adult growth… | Mar 2016 | Recommended | none received |
| somatropin Treatment of adults with severe growth hormone deficiency (GHD) and substantially impaired quality of life (QoL) at baseline. | Nov 2016 | Deferred | 68 individuals Australian Pituitary Foundation · Endocrine Society of Australia · Pituitary Foundation |
Who spoke
Australian Pituitary Foundation · Endocrine Society of Australia · Pituitary Foundation
What the PBS pays
$38M in government benefit over 2024–25, across 20,050 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| somatropin | $28.9M |
| somatrogon | $9.3M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| lonapegsomatropinSKYTROFA lonapegsomatropin 11 mg powder and solvent for solution for i | 2025 | 9 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 10 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.